# Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06005493/  
OnCo record `nct06005493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD5863 in pancreatic ductal adenocarcinoma, run by AstraZeneca, now recruiting.

## Summary

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06005493 by AstraZeneca, with 280 participants planned, started 2023-07-11 and due to reach its primary completion in 2027-07-16. Interventions recorded: AZD5863. Conditions listed: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06005493
- Phase: 1/2
- Setting: A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors
- Sponsor: AstraZeneca
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06005493: https://clinicaltrials.gov/study/NCT06005493

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [AZD5863](https://onco.cc/drugs/azd5863/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06005493.json